Inovio Product Pipeline
Inovio's electroporation-based DNA delivery technology has applicability to a broad spectrum of next-generation vaccines and immunotherapies. The company is focused on a promising, emerging field encompassing DNA-based immunotherapies and DNA vaccines, which are the focus of significant development effort because of their potential to provide both preventive and/or therapeutic treatments against.
The products being pursued by Inovio and partners, as outlined in the following sections, consist of two basic components: a DNA-based immunotherapy or DNA vaccine; and one of Inovio's electroporation-based DNA delivery systems. These experimental products are highlighted in the following sections, which are divided into the categories of cancers and infectious diseases.
Below is a graphical summary of the pre-clinical and clinical programs using Inovio technology.
